BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27321283)

  • 1. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
    Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
    Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
    Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
    Zhao Y; Zhao X; Chen V; Feng Y; Wang L; Croniger C; Conlon RA; Markowitz S; Fearon E; Puchowicz M; Brunengraber H; Hao Y; Wang Z
    Sci Rep; 2019 Dec; 9(1):19180. PubMed ID: 31844152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
    Zhao Y; Feng X; Chen Y; Selfridge JE; Gorityala S; Du Z; Wang JM; Hao Y; Cioffi G; Conlon RA; Barnholtz-Sloan JS; Saltzman J; Krishnamurthi SS; Vinayak S; Veigl M; Xu Y; Bajor DL; Markowitz SD; Meropol NJ; Eads JR; Wang Z
    Cancer Res; 2020 Nov; 80(21):4815-4827. PubMed ID: 32907836
    [No Abstract]   [Full Text] [Related]  

  • 5. Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in
    Miller SA; Policastro RA; Savant SS; Sriramkumar S; Ding N; Lu X; Mohammad HP; Cao S; Kalin JH; Cole PA; Zentner GE; O'Hagan HM
    Mol Cancer Res; 2020 Feb; 18(2):264-277. PubMed ID: 31704733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
    Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
    Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
    Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
    Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
    Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
    Bäumer N; Rehkämper J; Appel N; Terheyden L; Hartmann W; Wardelmann E; Buchholz F; Müller-Tidow C; Berdel WE; Bäumer S
    PLoS One; 2018; 13(7):e0200163. PubMed ID: 30001368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glutamine metabolism in
    Feng X; Hao Y; Wang Z
    Genes Dis; 2016 Dec; 3(4):241-243. PubMed ID: 30258894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
    Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
    Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
    Samuels Y; Diaz LA; Schmidt-Kittler O; Cummins JM; Delong L; Cheong I; Rago C; Huso DL; Lengauer C; Kinzler KW; Vogelstein B; Velculescu VE
    Cancer Cell; 2005 Jun; 7(6):561-73. PubMed ID: 15950905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
    Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
    Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
    Wang Y; Tang Q; Li M; Jiang S; Wang X
    Biochem Biophys Res Commun; 2014 Feb; 444(2):199-204. PubMed ID: 24440701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockin of mutant PIK3CA activates multiple oncogenic pathways.
    Gustin JP; Karakas B; Weiss MB; Abukhdeir AM; Lauring J; Garay JP; Cosgrove D; Tamaki A; Konishi H; Konishi Y; Mohseni M; Wang G; Rosen DM; Denmeade SR; Higgins MJ; Vitolo MI; Bachman KE; Park BH
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2835-40. PubMed ID: 19196980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.